Daily Stock Analysis, ADRO, Aduro Biotech Inc, priceseries

Aduro Biotech Inc. Daily Stock Analysis
Stock Information
Open
10.05
Close
10.20
High
10.30
Low
9.90
Previous Close
10.00
Daily Price Gain
0.20
YTD High
12.55
YTD High Date
Jan 9, 2017
YTD Low
8.75
YTD Low Date
Apr 5, 2017
YTD Price Change
-1.10
YTD Gain
-9.73%
52 Week High
16.43
52 Week High Date
Aug 4, 2016
52 Week Low
8.75
52 Week Low Date
Apr 5, 2017
52 Week Price Change
-0.71
52 Week Gain
-6.51%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Oct 14. 2015
21.83
Nov 12. 2015
27.28
21 Trading Days
24.96%
Link
LONG
Mar 31. 2016
12.81
Apr 11. 2016
13.70
7 Trading Days
6.93%
Link
LONG
Jun 29. 2016
10.98
Aug 11. 2016
14.84
30 Trading Days
35.12%
Link
LONG
Nov 7. 2016
12.15
Nov 22. 2016
13.80
11 Trading Days
13.61%
Link
Company Information
Stock Symbol
ADRO
Exchange
NasdaqGS
Company URL
http://www.aduro.com
Company Phone
510-848-4400
CEO
Stephen T. Isaacs
Headquarters
California
Business Address
626 BANCROFT WAY, SUITE 3-C, BERKELEY, CA 94710
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001435049
About

Aduro BioTech, Inc., a clinical-stage immunotherapy company, focuses on the discovery, development, and commercialization that transform the treatment of challenging diseases.

Description

Aduro BioTech, Inc., a clinical-stage immunotherapy company, focuses on the discovery, development, and commercialization that transform the treatment of challenging diseases. Its lead product candidate is CRS-207, an immuno-oncology therapy, which is in a Phase IIb clinical trial for the treatment of metastatic pancreatic cancer, unresectable malignant pleural mesothelioma, and ovarian cancer. The company also offers STING Pathway Activator product candidates that are synthetic small molecule immune modulators, which target and activate Stimulator of Interferon Genes receptor under collaboration with Novartis Pharmaceuticals Corporation; and develops monoclonal antibodies with the potential to yield immunotherapy. Aduro BioTech, Inc. also has a collaboration agreement with Janssen Biotech, Inc. to develop drugs for the treatment of prostate and lung cancers. The company was formerly known as Oncologic, Inc. and changed its name to Aduro BioTech, Inc. in June 2008. Aduro BioTech, Inc. was founded in 2000 and is based in Berkeley, California.